Antifungal de-escalation was not associated with adverse outcome in critically ill patients treated for invasive candidiasis: post hoc analyses of the AmarCAND2 study data.
about
Intensive care medicine research agenda on invasive fungal infection in critically ill patients.Management of intra-abdominal infections: recommendations by the WSES 2016 consensus conferenceCharacteristics and outcomes of anti-infective de-escalation during health care-associated intra-abdominal infectionsContribution of Candida biomarkers and DNA detection for the diagnosis of invasive candidiasis in ICU patients with severe abdominal conditionsDeterminants of Deescalation Failure in Critically Ill Patients with Sepsis: A Prospective Cohort Study.The risk and clinical outcome of candidemia depending on underlying malignancy.The current treatment landscape: candidiasis.Clinical characteristics and predictors of mortality in cirrhotic patients with candidemia and intra-abdominal candidiasis: a multicenter study.Echinocandin to fluconazole step-down therapy in critically ill patients with invasive, susceptible Candida albicans infections.Testing Antifungal Vaccines in an Animal Model of Invasive Candidiasis and in Human Mucosal Candidiasis.Focus on infection and sepsis in intensive care patients.Biomarker-based strategy for early discontinuation of empirical antifungal treatment in critically ill patients: a randomized controlled trial.What has changed in the treatment of invasive candidiasis? A look at the past 10 years and ahead.Principles of antimicrobial stewardship for bacterial and fungal infections in ICU.Biomarker-guided antifungal therapy in patients with suspected invasive candidiasis: Ready for prime time?De-escalation of antifungal treatment in critically ill patients with suspected invasive Candida infection: incidence, associated factors, and safety.
P2860
Q30235457-C37A16AF-EB5F-456F-ADA0-2E8B21B13437Q33640559-43384F0E-0D27-4166-85D8-D2CCAA99DA30Q36774787-694583C8-E5D8-495D-8852-9DA8321A907FQ36902916-02AA5BDD-992B-438A-9F60-0522D9B65D03Q37132283-61164B0A-2608-4431-AA8C-D40062462705Q37742252-0A6510AC-2D6A-4FDA-97BF-DEAD9B2234FCQ39018200-2934CDF9-5CEE-40C3-A139-063CAB5F18B5Q40066371-56BFF75C-57F2-4599-99BF-9518B7A0D5F6Q40168402-02F10220-1ABE-4787-9626-B8F370F5CBC6Q40183727-8B8C7004-4811-40B5-B112-A038E2B8D7E5Q40797788-FA413B62-ECC7-41FD-A504-D9C57AE413E8Q47678193-5A0FEB59-665E-4982-BA75-141C4FF2ADF0Q47749829-9FCD674F-20F3-4FD6-BFC9-1A88A545473BQ48357529-D1C8C56C-E135-49BD-860A-D5D0B625270BQ50101377-CA959FA2-A7EF-4537-B9D5-E13A2415EA2FQ52575674-A23184E7-B25B-4873-88CC-138EDA493FAF
P2860
Antifungal de-escalation was not associated with adverse outcome in critically ill patients treated for invasive candidiasis: post hoc analyses of the AmarCAND2 study data.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Antifungal de-escalation was n ...... s of the AmarCAND2 study data.
@ast
Antifungal de-escalation was n ...... s of the AmarCAND2 study data.
@en
type
label
Antifungal de-escalation was n ...... s of the AmarCAND2 study data.
@ast
Antifungal de-escalation was n ...... s of the AmarCAND2 study data.
@en
prefLabel
Antifungal de-escalation was n ...... s of the AmarCAND2 study data.
@ast
Antifungal de-escalation was n ...... s of the AmarCAND2 study data.
@en
P2093
P2860
P50
P1476
Antifungal de-escalation was n ...... s of the AmarCAND2 study data.
@en
P2093
Elie Azoulay
Hervé Dupont
Jean-Michel Constantin
Jean-Pierre Gangneux
Olivier Leroy
Philippe Montravers
Pierre-François Perrigault
Sébastien Bailly
P2860
P2888
P304
P356
10.1007/S00134-015-4053-1
P577
2015-09-14T00:00:00Z